Influenza B Infections - Pipeline Review, H2 2016

  • ID: 3832338
  • Report
  • 71 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • AbbVie Inc.
  • Altravax, Inc.
  • Aphios Corporation
  • ContraFect Corporation
  • Humabs BioMed SA
  • Johnson & Johnson
  • MORE
Influenza B Infections - Pipeline Review, H2 2016

Summary

‘Influenza B Infections - Pipeline Review, H2 2016’, provides an overview of the Influenza B Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Influenza B Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Influenza B Infections and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Influenza B Infections
- The report reviews pipeline therapeutics for Influenza B Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Influenza B Infections therapeutics and enlists all their major and minor projects
- The report assesses Influenza B Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Influenza B Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Influenza B Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Influenza B Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • AbbVie Inc.
  • Altravax, Inc.
  • Aphios Corporation
  • ContraFect Corporation
  • Humabs BioMed SA
  • Johnson & Johnson
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Influenza B Infections Overview

Therapeutics Development

Pipeline Products for Influenza B Infections - Overview

Pipeline Products for Influenza B Infections - Comparative Analysis

Influenza B Infections - Therapeutics under Development by Companies

Influenza B Infections - Therapeutics under Investigation by Universities/Institutes

Influenza B Infections - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Influenza B Infections - Products under Development by Companies

Influenza B Infections - Products under Investigation by Universities/Institutes

Influenza B Infections - Companies Involved in Therapeutics Development

AbbVie Inc.

Altravax, Inc.

Aphios Corporation

BioClonetics Immunotherapeutics, Inc.

ContraFect Corporation

Humabs BioMed SA

Johnson & Johnson

Medicago Inc.

MedImmune, LLC

Mucosis B.V.

Sanofi Pasteur SA

Vaxart, Inc.

Zydus Cadila Healthcare Limited

Influenza B Infections - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

AL-18 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APP-0205 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APP-309 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CF-403 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CR-8033 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CR-8071 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CR-9114 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fluad (quadrivalent) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FluGEM - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [serotype B] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [serotypes A, B] (split virion, tetravalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [serotypes A, B] (virus like particle) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (tetravalent, split virion) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent, virus like particle) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody for Influenza B - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody for Influenza B Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VXABYW-10 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Influenza B Infections - Dormant Projects

Influenza B Infections - Discontinued Products

Influenza B Infections - Product Development Milestones

Featured News & Press Releases

Dec 17, 2015: Vaxart Announces Enrollment of First Patient in Influenza B Phase 1 Trial

Mar 11, 2011: Sanofi Pasteur And Daiichi Sankyo Announce Voluntary Recall Of Hemophilus Influenza Type B Conjugate Vaccine

Apr 23, 1993: FDA Approval of Use of a New Haemophilus b Conjugate Vaccine and a Combined Diphtheria-Tetanus-Pertussis and Haemophilus b Conjugate Vaccine for Infants and Children

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 71List of Tables

Number of Products under Development for Influenza B Infections, H2 2016

Number of Products under Development for Influenza B Infections - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Influenza B Infections - Pipeline by AbbVie Inc., H2 2016

Influenza B Infections - Pipeline by Altravax, Inc., H2 2016

Influenza B Infections - Pipeline by Aphios Corporation, H2 2016

Influenza B Infections - Pipeline by BioClonetics Immunotherapeutics, Inc., H2 2016

Influenza B Infections - Pipeline by ContraFect Corporation, H2 2016

Influenza B Infections - Pipeline by Humabs BioMed SA, H2 2016

Influenza B Infections - Pipeline by Johnson & Johnson, H2 2016

Influenza B Infections - Pipeline by Medicago Inc., H2 2016

Influenza B Infections - Pipeline by MedImmune, LLC, H2 2016

Influenza B Infections - Pipeline by Mucosis B.V., H2 2016

Influenza B Infections - Pipeline by Sanofi Pasteur SA, H2 2016

Influenza B Infections - Pipeline by Vaxart, Inc., H2 2016

Influenza B Infections - Pipeline by Zydus Cadila Healthcare Limited, H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Influenza B Infections - Dormant Projects, H2 2016

Influenza B Infections - Discontinued Products, H2 2016 67List of Figures

Number of Products under Development for Influenza B Infections, H2 2016

Number of Products under Development for Influenza B Infections - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Targets, H2 2016

Number of Products by Stage and Targets, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • AbbVie Inc.
  • Altravax, Inc.
  • Aphios Corporation
  • ContraFect Corporation
  • Humabs BioMed SA
  • Johnson & Johnson
  • MORE
Influenza B Infections Type B influenza is a subtype of the influenza virus that tends to occur sporadically. Symptoms include runny nose, sore throat, aching muscles, malaise, watery eyes, aching body, loss of appetite and weakness. Treatment includes antiviral, analgesics and antipyretics medications.

Influenza B Infections pipeline therapeutics constitutes close to 24 molecules. Out of which approximately 21 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 6, 1, 2, 6 and 4 respectively. Similarly, the Universities portfolio in Phase I and Discovery stages comprises 2 and 1 molecules, respectively.

Our latest report Influenza B Infections – Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Influenza B Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Influenza B Infections and features dormant and discontinued projects.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
AbbVie Inc.
Altravax, Inc.
Aphios Corporation
BioClonetics Immunotherapeutics, Inc.
ContraFect Corporation
Humabs BioMed SA
Johnson & Johnson
Medicago Inc.
MedImmune, LLC
Mucosis B.V.
Sanofi Pasteur SA
Vaxart, Inc.
Zydus Cadila Healthcare Limited
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll